MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system

36Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

Abstract

Primary diffuse large B-cell lymphoma of the central nervous system (CNS DLBCL) is a rare, aggressive subtype of DLBCL, the biology of which is poorly understood. Recent studies have suggested a prognostic role of MYC protein expression in systemic DLBCL, but little is known about the frequency and significance of MYC protein expression in CNS DLBCL. Hence, we investigated MYC protein expression profiles of CNS DLBCL and assessed the relationship between MYC expression and a variety of histopathologic, immunophenotypic, genetic, and clinical features. Fifty-nine CNS DLBCL diagnosed at our institution over the past 13 years were evaluated. The majority of cases (80%) showed centroblastic morphology, and 12 (20%) displayed a perivascular pattern of infiltration. According to the Hans criteria, 41 (69%) cases had a non-germinal center B-cell and 18 (31%) had a germinal center B-cell cell-of-origin (COO) phenotype. Mean MYC protein expression was 50% (median: 50%, range: 10-80%). Forty-three cases (73%) showed MYC overexpression (>40%), and 35 (60%) showed MYC/BCL2 coexpression. MYC overexpression was seen in the single case harboring MYC translocation and in the cases showing increased copies of MYC (27%); however, no significant difference in mean MYC expression was seen between groups harboring or lacking MYC aberrations. In our series, age was associated with a significantly increased risk of death, and the perivascular pattern of infiltration was associated with a significantly increased risk of disease progression. Neither MYC expression (with or without BCL2 coexpression) nor other variables, including COO subtype were predictive of clinical outcome. Our findings indicate that the proportion of CNS DLBCL overexpressing MYC is higher compared to systemic DLBCL, and MYC overexpression appears to be independent of genetic MYC abnormalities. Thus, MYC expression and other immunophenotypic markers used for prognostication of systemic DLBCL might not apply to CNS DLBCL due to differences in disease biology. Copyright:

References Powered by Scopus

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

3672Citations
N/AReaders
Get full text

MYC on the path to cancer

2658Citations
N/AReaders
Get full text

MiR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis

1218Citations
N/AReaders
Get full text

Cited by Powered by Scopus

PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival

48Citations
N/AReaders
Get full text

High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

44Citations
N/AReaders
Get full text

MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system

39Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Gill, K. Z., Iwamoto, F., Allen, A., Hoehn, D., Murty, V. V., Alobeid, B., & Bhagat, G. (2014). MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system. PLoS ONE, 9(12). https://doi.org/10.1371/journal.pone.0114398

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 15

60%

Researcher 7

28%

Professor / Associate Prof. 2

8%

Lecturer / Post doc 1

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 22

69%

Agricultural and Biological Sciences 5

16%

Biochemistry, Genetics and Molecular Bi... 4

13%

Chemistry 1

3%

Save time finding and organizing research with Mendeley

Sign up for free